[Correspondence] Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial

John Deanfield and colleagues reported that semaglutide reduces major adverse cardiovascular events (MACE) independent of weight loss.1 However, this conclusion relies on conditioning on a post-randomisation mediator (weight loss), which is a method known to potentially introduce collider stratifica